GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women

Eva Pers Winning Iepsen; Julie Rehné Lundgren; Bolette Hartmann; Oluf Pedersen; Torben Hansen; Niklas R Jørgensen; Jens-Erik Beck Jensen; Jens J Holst; Sten Madsbad; Signe Sørensen Torekov

doi:10.1210/jc.2015-1176

GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women

Eva Pers Winning Iepsen, Julie Rehné Lundgren, Bolette Hartmann, Oluf Pedersen, Torben Hansen, Niklas R Jørgensen, Jens-Erik Beck Jensen, Jens J Holst, Sten Madsbad, Signe Sørensen Torekov

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

131 Citationer (Scopus)

Abstract

CONTEXT: Recent studies indicate that glucagon-like peptide 1 (GLP-1) regulates bone turnover, but the effects of GLP-1 receptor agonists (GLP-1 RAs) on bone in obese weight-reduced individuals are unknown.

OBJECTIVE: To investigate the role of GLP-1 RAs on bone formation and weight loss induced bone mass reductions.

DESIGN: Randomized control study.

SETTING: Out-patient research hospital clinic.

PARTICIPANTS: Thirty-seven healthy obese women. BMI 34±0.5 kg/m(2), age 46±2 years.

INTERVENTION: After a low-calorie diet-induced 12% weight loss, participants were randomized to treatment with or without administration of the GLP-1 RA liraglutide (1.2mg/day) for 52 weeks. In case of weight gain, up to two meals per day could be substituted with a low-calorie diet product in order to maintain the weight loss.

MAIN OUTCOME MEASURES: Total, pelvic and arm-leg bone mineral content (BMC) and bone markers (CTX-1 and P1NP) were investigated before, after weight loss and after 52 weeks weight maintenance. Primary end points: Change in BMC and bone markers after 52 weeks weight maintenance with or without GLP-1 RA treatment.

RESULTS: Total, pelvic and arm-leg BMC decreased during weight maintenance in the control group (p<0.0001), but not significantly in the liraglutide group. Thus, total and arm-leg BMC loss was 4 times greater in the control group compared to the liraglutide group (estimated difference 27g (95% CI 5-48), p=0.01), although the 12% weight loss was maintained in both groups. In the liraglutide group, the bone formation marker P1NP increased by 16% (7±3 μg/L) vs a 2% (-1±4 μg/L) decrease in the control group (p<0.05). The bone resorption marker CTX-1 did not change during the weight loss maintenance phase.

CONCLUSIONS: Treatment with a long-acting GLP-1 RA increased bone formation by 16% and prevented bone loss after weight loss obtained through a low calorie-diet, supporting its role as a safe weight-lowering agent.

Originalsprog	Engelsk
Tidsskrift	The Journal of clinical endocrinology and metabolism
Vol/bind	100
Udgave nummer	8
Sider (fra-til)	2909 –2917
Antal sider	9
ISSN	0021-972X
DOI	https://doi.org/10.1210/jc.2015-1176
Status	Udgivet - 2015

Adgang til dokumentet

10.1210/jc.2015-1176

Citationsformater

Iepsen, E. P. W., Lundgren, J. R., Hartmann, B., Pedersen, O., Hansen, T., Jørgensen, N. R., Jensen, J-E. B., Holst, J. J., Madsbad, S., & Torekov, S. S. (2015). GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women. The Journal of clinical endocrinology and metabolism, 100(8), 2909 –2917. https://doi.org/10.1210/jc.2015-1176

GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women. / Iepsen, Eva Pers Winning; Lundgren, Julie Rehné; Hartmann, Bolette ; Pedersen, Oluf ; Hansen, Torben ; Jørgensen, Niklas R; Jensen, Jens-Erik Beck; Holst, Jens J ; Madsbad, Sten ; Torekov, Signe Sørensen.

I: The Journal of clinical endocrinology and metabolism, Bind 100, Nr. 8, 2015, s. 2909 –2917.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Iepsen, EPW, Lundgren, JR, Hartmann, B , Pedersen, O , Hansen, T , Jørgensen, NR, Jensen, J-EB, Holst, JJ , Madsbad, S & Torekov, SS 2015, 'GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women', The Journal of clinical endocrinology and metabolism, bind 100, nr. 8, s. 2909 –2917. https://doi.org/10.1210/jc.2015-1176

Iepsen, Eva Pers Winning ; Lundgren, Julie Rehné ; Hartmann, Bolette ; Pedersen, Oluf ; Hansen, Torben ; Jørgensen, Niklas R ; Jensen, Jens-Erik Beck ; Holst, Jens J ; Madsbad, Sten ; Torekov, Signe Sørensen. / GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women. I: The Journal of clinical endocrinology and metabolism. 2015 ; Bind 100, Nr. 8. s. 2909 –2917.

@article{644b8c86e0264afb90a0bf6ef0cb5a63,

title = "GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women",

abstract = "CONTEXT: Recent studies indicate that glucagon-like peptide 1 (GLP-1) regulates bone turnover, but the effects of GLP-1 receptor agonists (GLP-1 RAs) on bone in obese weight-reduced individuals are unknown.OBJECTIVE: To investigate the role of GLP-1 RAs on bone formation and weight loss induced bone mass reductions.DESIGN: Randomized control study.SETTING: Out-patient research hospital clinic.PARTICIPANTS: Thirty-seven healthy obese women. BMI 34±0.5 kg/m(2), age 46±2 years.INTERVENTION: After a low-calorie diet-induced 12% weight loss, participants were randomized to treatment with or without administration of the GLP-1 RA liraglutide (1.2mg/day) for 52 weeks. In case of weight gain, up to two meals per day could be substituted with a low-calorie diet product in order to maintain the weight loss.MAIN OUTCOME MEASURES: Total, pelvic and arm-leg bone mineral content (BMC) and bone markers (CTX-1 and P1NP) were investigated before, after weight loss and after 52 weeks weight maintenance. Primary end points: Change in BMC and bone markers after 52 weeks weight maintenance with or without GLP-1 RA treatment.RESULTS: Total, pelvic and arm-leg BMC decreased during weight maintenance in the control group (p<0.0001), but not significantly in the liraglutide group. Thus, total and arm-leg BMC loss was 4 times greater in the control group compared to the liraglutide group (estimated difference 27g (95% CI 5-48), p=0.01), although the 12% weight loss was maintained in both groups. In the liraglutide group, the bone formation marker P1NP increased by 16% (7±3 μg/L) vs a 2% (-1±4 μg/L) decrease in the control group (p<0.05). The bone resorption marker CTX-1 did not change during the weight loss maintenance phase.CONCLUSIONS: Treatment with a long-acting GLP-1 RA increased bone formation by 16% and prevented bone loss after weight loss obtained through a low calorie-diet, supporting its role as a safe weight-lowering agent.",

author = "Iepsen, {Eva Pers Winning} and Lundgren, {Julie Rehn{\'e}} and Bolette Hartmann and Oluf Pedersen and Torben Hansen and J{\o}rgensen, {Niklas R} and Jensen, {Jens-Erik Beck} and Holst, {Jens J} and Sten Madsbad and Torekov, {Signe S{\o}rensen}",

year = "2015",

doi = "10.1210/jc.2015-1176",

language = "English",

volume = "100",

pages = "2909 –2917",

journal = "Journal of Clinical Endocrinology and Metabolism",

issn = "0021-972X",

publisher = "Oxford University Press",

number = "8",

}

TY - JOUR

T1 - GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women

AU - Iepsen, Eva Pers Winning

AU - Lundgren, Julie Rehné

AU - Hartmann, Bolette

AU - Pedersen, Oluf

AU - Hansen, Torben

AU - Jørgensen, Niklas R

AU - Jensen, Jens-Erik Beck

AU - Holst, Jens J

AU - Madsbad, Sten

AU - Torekov, Signe Sørensen

PY - 2015

Y1 - 2015

N2 - CONTEXT: Recent studies indicate that glucagon-like peptide 1 (GLP-1) regulates bone turnover, but the effects of GLP-1 receptor agonists (GLP-1 RAs) on bone in obese weight-reduced individuals are unknown.OBJECTIVE: To investigate the role of GLP-1 RAs on bone formation and weight loss induced bone mass reductions.DESIGN: Randomized control study.SETTING: Out-patient research hospital clinic.PARTICIPANTS: Thirty-seven healthy obese women. BMI 34±0.5 kg/m(2), age 46±2 years.INTERVENTION: After a low-calorie diet-induced 12% weight loss, participants were randomized to treatment with or without administration of the GLP-1 RA liraglutide (1.2mg/day) for 52 weeks. In case of weight gain, up to two meals per day could be substituted with a low-calorie diet product in order to maintain the weight loss.MAIN OUTCOME MEASURES: Total, pelvic and arm-leg bone mineral content (BMC) and bone markers (CTX-1 and P1NP) were investigated before, after weight loss and after 52 weeks weight maintenance. Primary end points: Change in BMC and bone markers after 52 weeks weight maintenance with or without GLP-1 RA treatment.RESULTS: Total, pelvic and arm-leg BMC decreased during weight maintenance in the control group (p<0.0001), but not significantly in the liraglutide group. Thus, total and arm-leg BMC loss was 4 times greater in the control group compared to the liraglutide group (estimated difference 27g (95% CI 5-48), p=0.01), although the 12% weight loss was maintained in both groups. In the liraglutide group, the bone formation marker P1NP increased by 16% (7±3 μg/L) vs a 2% (-1±4 μg/L) decrease in the control group (p<0.05). The bone resorption marker CTX-1 did not change during the weight loss maintenance phase.CONCLUSIONS: Treatment with a long-acting GLP-1 RA increased bone formation by 16% and prevented bone loss after weight loss obtained through a low calorie-diet, supporting its role as a safe weight-lowering agent.

AB - CONTEXT: Recent studies indicate that glucagon-like peptide 1 (GLP-1) regulates bone turnover, but the effects of GLP-1 receptor agonists (GLP-1 RAs) on bone in obese weight-reduced individuals are unknown.OBJECTIVE: To investigate the role of GLP-1 RAs on bone formation and weight loss induced bone mass reductions.DESIGN: Randomized control study.SETTING: Out-patient research hospital clinic.PARTICIPANTS: Thirty-seven healthy obese women. BMI 34±0.5 kg/m(2), age 46±2 years.INTERVENTION: After a low-calorie diet-induced 12% weight loss, participants were randomized to treatment with or without administration of the GLP-1 RA liraglutide (1.2mg/day) for 52 weeks. In case of weight gain, up to two meals per day could be substituted with a low-calorie diet product in order to maintain the weight loss.MAIN OUTCOME MEASURES: Total, pelvic and arm-leg bone mineral content (BMC) and bone markers (CTX-1 and P1NP) were investigated before, after weight loss and after 52 weeks weight maintenance. Primary end points: Change in BMC and bone markers after 52 weeks weight maintenance with or without GLP-1 RA treatment.RESULTS: Total, pelvic and arm-leg BMC decreased during weight maintenance in the control group (p<0.0001), but not significantly in the liraglutide group. Thus, total and arm-leg BMC loss was 4 times greater in the control group compared to the liraglutide group (estimated difference 27g (95% CI 5-48), p=0.01), although the 12% weight loss was maintained in both groups. In the liraglutide group, the bone formation marker P1NP increased by 16% (7±3 μg/L) vs a 2% (-1±4 μg/L) decrease in the control group (p<0.05). The bone resorption marker CTX-1 did not change during the weight loss maintenance phase.CONCLUSIONS: Treatment with a long-acting GLP-1 RA increased bone formation by 16% and prevented bone loss after weight loss obtained through a low calorie-diet, supporting its role as a safe weight-lowering agent.

U2 - 10.1210/jc.2015-1176

DO - 10.1210/jc.2015-1176

M3 - Journal article

C2 - 26043228

VL - 100

SP - 2909

EP - 2917

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 8

ER -